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Abstract
Objectives—To evaluate severe (grade 3/4) morbidity and mortality in HIV-exposed, uninfected 
infants.
Design—Secondary data analysis of The Breastfeeding, Antiretrovirals, and Nutrition (BAN) 
clinical trial.
Methods—BAN randomized 2369 mother–infant pairs to maternal, infant, or no extended 
antiretroviral prophylaxis during breastfeeding. Morbidity outcomes examined were pneumonia/
serious febrile illness, diarrhea/growth faltering, and malaria. Infant death was defined as neonatal 
(≤ 30 days of life), and postneonatal (31 days to 48 weeks of life). Cox proportional hazards 
models were used to evaluate the effect of covariates on infant morbidity and mortality.
Results—The rate of pneumonia/serious febrile illness was highest in the first 12 weeks 
(0.83/100 person-weeks) before rapidly decreasing; rates of all morbidity outcomes increased after 
24 weeks. Rates of pneumonia/serious febrile illness and diarrhea/growth faltering were higher 
during the rainy season. Prophylactic infant cotrimoxazole significantly decreased the rates of all 
morbidity outcomes. White blood cell (WBC) count less than 9000/μl at birth was associated with 
increased diarrhea/growth faltering [adjusted hazard ratio (aHR) 1.73, P = 0.04] and malaria (aHR 
2.18, P = 0.02). Low birth weight (2000–2499 g) was associated with neonatal death (aHR 12.3, P 
<0.001). Factors associated with postneonatal death included rainy season (aHR 4.24, P = 0.002), 
infant cotrimoxazole (aHR 0.48, P = 0.03), and low infant WBC count at birth (aHR 2.53, P = 
0.02).
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Conclusion—Infant morbidity rates increased after 24 weeks, when BAN infants weaned. 
Introduction of prophylactic cotrimoxazole was associated with reduced rates of morbidity and 
mortality in HIV-exposed uninfected infants. Unexpectedly, a low WBC count at birth was 
significantly associated with later infant morbidity and mortality in this cohort.
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Introduction
Infant morbidity and mortality has been greatly affected by the HIV epidemic in many 
resource-limited settings. Although the numbers of new infant HIV infections are expected 
to decrease as antiretroviral prophylaxis is now recommended by WHO during gestation, 
delivery, and breastfeeding for HIV-infected women [1], the number of infants who are 
HIV-exposed but uninfected will proportionately increase. Examining the determinants of 
these infants’ morbidity and mortality is, therefore, of increasing importance. Infant 
mortality is affected by many factors such as geographic and socioeconomic setting, feeding 
type, and the mother’s HIV status and disease stage. Pooled analyses of data from African 
studies indicate a mortality of HIV-exposed infants between 39.3 and 49 per 1000 [2,3]. 
Mortality of these infants is two to four times as high as that of HIV-unexposed infants in 
the same setting [4,5], and is even higher for infants of mothers who had advanced HIV 
disease or who died [3–6]. Morbidity is also higher among HIV-exposed infants compared 
to their unexposed counterparts. In the ZVITAMBO cohort, HIV-exposed uninfected infants 
made an average of 30% more sick clinic visits and had 20% more hospitalizations than 
unexposed infants [5]. Respiratory and gastrointestinal infections are the main causes of 
infant morbidity and mortality [6,7], with malaria also contributing substantially in endemic 
areas [8].
The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study, conducted from 2004 to 
2010 among 2369 mother–infant pairs in Lilongwe, Malawi, provides an opportunity to 
examine morbidity and mortality in a large cohort of HIV-exposed infants in a resource-
limited setting, almost all of whom were weaned at about 6 months of age. We examined the 
effect of several prognostic factors on infant morbidity and mortality.
Methods
Study design and participants
All infants were enrolled in the BAN randomized controlled trial, which has been described 
in detail elsewhere [9,10]. Briefly, investigators recruited women who tested HIV-positive 
through a prevention of mother-to-child transmission program at antenatal clinics in 
Lilongwe, Malawi, from April 2004 to January 2010. Primary eligibility criteria included 
age of at least 14 years, gestation of 30 weeks or less, a CD4+ T-cell count of 250/μl or more 
(before 24 July 2006, count ≥200/μl; change in accordance with Malawi Ministry of Health 
guidelines for HIV treatment), and no history of antiretroviral drug use (including the 
HIVNET 012 regimen) [11]. Mothers or infants who had postnatal conditions that would 
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preclude study interventions were excluded from the study, as were infants with birth weight 
less than 2000 g. All women provided written informed consent. The BAN study protocol 
was approved by the Malawi National Health Science Research Committee and by 
institutional review boards at the University of North Carolina (UNC) at Chapel Hill and the 
US Centers for Disease Control and Prevention (CDC).
Mother–infant pairs were randomized within 1 week of delivery to a two-group maternal 
nutritional intervention and to a three-group antiretroviral intervention consisting of a triple-
drug antiretroviral regimen for the mother (maternal-regimen group), daily dose of 
nevirapine for the infant (infant-regimen group), or neither (control antiretroviral group). 
Irrespective of antiretroviral treatment assignment, all mothers in labor and their newborn 
infants were given single-dose nevirapine and zidovudine and lamivudine for 7 days. The 
interventions began after delivery and were continued until the cessation of breastfeeding, 
but no longer than 28 weeks. Infants found to be HIV-infected at birth or in the first 2 weeks 
of life were disenrolled from the BAN study and referred for care.
All mothers in the study were counseled to breastfeed exclusively for the first 24 weeks of 
life, and to wean over a 4-week period; infants were provided with a weaning supplement (a 
locally produced ready-to-use therapeutic food) [12]. Exclusive breastfeeding was defined as 
providing no other liquids or foods except breast milk.
Mother–infant pairs were followed at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32, 36, 42, and 48 
weeks postpartum. The choice of a 48-week follow-up was made during the study design 
phase to most easily accommodate even spacing of study visits. Anthropometrics, vital 
signs, illnesses and hospitalizations since the last visit, current symptoms, and physical 
examination findings were collected at all follow-up visits. Participants were advised to 
return to the clinic between visits to receive treatment if the mother or child was ill. All 
infants received vaccines according to the Malawi immunization schedule, which included 
Bacillus Calmette–Guerin (BCG), and vaccines against tetanus, diphtheria, pertussis, 
Haemophilus influenzae, hepatitis B, poliomyelitis, and the conjugate pneumococcal 
vaccine.
Infants were tested for HIV-1 infection at birth and at 2, 12, 28, and 48 weeks with the use 
of the Roche Amplicor 1.5 DNA PCR assay (Roche Molecular Systems, Pleasanton, 
California, USA). Positive specimens were confirmed by testing a specimen obtained at the 
next visit. If an infant was lost to follow-up or died before a confirmatory test was obtained, 
then a second specimen from the same day was tested at the reference laboratory at UNC. 
For all positive infants, dried blood spots collected at all study visits were tested to narrow 
the window of seroconversion. Mother–infant pairs lost to follow-up were traced by a team 
of community nurses to determine HIV and vital status.
In accordance with the Malawi Ministry of Health and Population Guidelines and WHO 
guidelines, cotrimoxazole prophylaxis was initiated in the BAN study for eligible women 
and infants on 13 June 2006 [13]. Cotrimoxazole (240 mg once daily) was provided to all 
infants in the study beginning at 6 weeks of age through 36 weeks of age or until weaning 
occurred and HIV infection was ruled out. At the same time, cotrimoxazole was also 
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initiated for mothers whose CD4+ T-cell count was less than 500 cells/μl, measured during 
pregnancy.
We examined severe morbidity outcomes and mortality among these infants during 48 
weeks of follow-up. The analysis is limited to HIV-uninfected infants, by excluding infants 
HIV-infected by 2 weeks of life (thus, excluding perinatal infections), and by censoring 
infants who became infected during the study via breastfeeding at their last negative HIV 
test.
Morbidity and mortality outcomes
Morbidity and mortality data were derived from serious adverse events (SAEs) reported in 
the BAN study. SAEs were defined as any experience that was fatal or life-threatening, 
required in-patient hospitalization or prolongation of an existing hospitalization, or resulted 
in a persistent or significant disability or incapacity, and were graded according to toxicity 
tables from the National Institute of Allergy and Infectious Diseases, Division of AIDS 
(DAIDS) [14]. Infants were evaluated at all regular and interim sick visits for illnesses or 
clinical or laboratory abnormalities. If an illness met the criteria for an SAE, an SAE was 
reported. Growth faltering was defined by edema (due to malnutrition) or severe wasting 
(weight <70% expected for length) [15]. All diagnoses were based on clinical judgment and 
did not necessarily require microbiologic or other laboratory confirmation.
The following grade 3 or 4 infant morbidity outcomes were assessed between birth and 48 
weeks of life: pneumonia/serious febrile illness (SFI; SFI included diagnoses of ‘sepsis’ and 
meningitis; as a result, this outcome included respiratory and other, nongastrointestinal, 
infectious morbidity), diarrhea with or without growth faltering, and malaria. These three 
combined outcomes comprised the great majority of all infant clinical SAEs in BAN [16]. 
Infant mortality was examined separately for the neonatal period, defined as occurring in the 
first 30 days of life, and for the postneonatal period, defined as occurring between 31 days 
and 48 weeks of life.
Statistical analysis
Morbidity rates were estimated using person-weeks of follow-up during four 12-week infant 
age intervals (0–12, 13–24, 25–36, and 37–48 weeks), and by potential risk factors. Hazard 
ratios and 95% confidence intervals for morbidity and mortality outcomes were estimated 
using the Cox proportional hazards model. Conditional gap time models were used for 
morbidity outcomes with recurrent events [17]. The extended Kaplan–Meier method was 
used to estimate the probability of death by time-dependent covariates. The cutpoints used to 
define low hemoglobin and platelets were for grade 1 toxicity, according to DAIDS tables 
[14]; for white blood cell (WBC) counts at birth, it was a value accepted as the lower limit 
of normal range [18]. For newborn absolute neutrophil count (ANC), the DAIDS cutpoints 
were modified to account for the high prevalence of ethnic neutropenia [19], so that the 
grade 4 DAIDS cutpoint was used. Rainy season (defined as November through March), and 
maternal and infant cotrimoxazole prophylaxis were modeled as time-dependent covariates. 
All multivariable models were adjusted for antiretroviral treatment assignment and stratified 
by randomization to the maternal nutritional supplement.
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Role of the funding source
CDC representatives were part of the study team and were involved in the study design, 
coordination, data collection, data analysis, data interpretation, and writing of the report. The 
study group had full access to all study data and had final responsibility for the analysis, 
interpretation, and decision to submit for publication. The manufacturers of the study drugs 




Of 2369 mother–infant pairs enrolled in the BAN study, 119 (5.0%) infants tested HIV-
positive between 0 and 2 weeks of life and were excluded, resulting in a total of 2250 infants 
contributing data to this analysis (Table 1). The mothers’ self-reported frequency of 
exclusive breastfeeding at 24 weeks postpartum was 89%, which decreased to 7% by 28 
weeks postpartum. By 32 weeks postpartum, 94% of mothers reported no breastfeeding.
The majority of infants were born to married mothers (93%), mothers with only primary 
education or less (65%), and in homes without electricity (81%). Most infants (68%) were 
born after cotrimoxazole prophylaxis was introduced in the study. Nearly 8% of infants were 
born with low birth weight (2000–2499 g). Almost 7% of the newborns had a WBC count at 
birth less than 9000/dl.
Infant morbidity
The overall incidence rate for clinical grade 3/4 SAEs between 0 and 48 weeks of age was 
0.744 per 100 person-weeks. The incidence rate for pneumonia/SFI was 0.430 per 100 
person-weeks; for diarrhea/growth faltering, it was 0.170 per 100 person-weeks; and for 
malaria, 0.100 per 100 person-weeks. The rate of pneumonia/SFI was highest in the first 12 
weeks of life, before rapidly decreasing (Table 2). After 24 weeks of age, an increase in 
pneumonia/SFI was observed for the rest of the infants’ first year of life. Diarrhea/growth 
faltering and malaria rates increased steadily from birth, and were highest between 37 and 
48 weeks (Table 2).
The effects of several factors on each morbidity outcome were examined. Infant 
cotrimoxazole prophylaxis was associated with a significant decrease in the rate of 
morbidity for all three studied outcomes in adjusted models (Table 3), with the strongest 
protective effect observed for malaria [adjusted hazard ratio (aHR) = 0.36, P <0.001]. Other 
independent factors associated with pneumonia/SFI were rainy season (aHR = 1.53, P 
<0.001) and low infant ANC count at delivery (<1500/μl; aHR 2.32, P = 0.02). Rainy season 
was also significantly associated with diarrhea/growth faltering in adjusted models (aHR = 
1.49, P = 0.02). Low maternal hemoglobin at delivery and low infant WBC count (<9000/μl) 
at delivery were independently associated with both diarrhea/growth faltering and malaria. 
Low platelet count at birth (<85 000/μl) was significantly associated with subsequent severe 
malaria (aHR = 3.00, P = 0.04).
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Antiretroviral prophylaxis arm assignment (maternal or infant antiretrovirals or no extended 
antiretroviral prophylaxis during breastfeeding), antenatal maternal CD4+ T-cell count (200–
350 or >350 cells/μl), and birth weight were not significantly associated with any of the 
morbidity outcomes examined.
In a sensitivity analysis removing morbidity outcomes before infant cotrimoxazole 
prophylaxis was started at 6 weeks of life, infant cotrimoxazole remained significantly 
associated with all three morbidity outcomes. Electricity in the home was associated with a 
significant decrease in the rates of pneumonia/SFI (aHR = 0.57, P = 0.02) and diarrhea/
growth faltering (aHR = 0.32, P = 0.01). However, as this variable was only collected on a 
subset of BAN participants (46%), it was not included in the main analysis.
Infant mortality in the first 48 weeks of life
There were a total of 56 deaths among HIV-uninfected infants between birth and 48 weeks 
of life, of which 10 were in the neonatal period. This represents a neonatal mortality rate of 
0.056 per person-year and an overall infant mortality rate of 0.034 per person-year in HIV-
uninfected infants (0.027 from 0 to 28 weeks and 0.046 per person-year from 28 to 48 
weeks). The only significant factor associated with neonatal death in an adjusted model was 
low birth weight (2000–2499 g, aHR = 12.3, P <0.001; Table 4). Low infant ANC count at 
birth was significantly associated with neonatal death in an unadjusted model (hazard ratio = 
13.2, P = 0.02), but this association did not remain after adjustment for other risk factors. 
The effects of maternal CD4+ T-cell count, maternal anemia, and rainy season on neonatal 
mortality did not reach statistical significance; similarly, a protective effect of maternal 
prophylaxis with cotrimoxazole was not statistically significant.
Independent factors associated with postneonatal infant death included rainy season (aHR = 
4.24, P = 0.002), infant cotrimoxazole prophylaxis (aHR = 0.48, P = 0.03), and low infant 
WBC count at birth (aHR = 2.53, P = 0.02). Maternal CD4+ T-cell count did not have a 
significant effect on postneonatal infant mortality.
Figure 1 depicts infant survival by receipt of cotrimoxazole prophylaxis and by low WBC 
count at birth using Kaplan–Meier or extended Kaplan–Meier analysis.
Discussion
Our findings raise several points. First, and as would be expected for HIV-unexposed infants 
[5,8], the highest rates of respiratory and other infectious (with the exception of 
gastrointestinal) morbidity were seen in the neonatal and early infant life. In contrast, serious 
malaria morbidity peaked later in the first year of life, consistent with other studies that have 
shown an increase in malarial morbidity and mortality after 6 months of age in seasonal 
transmission areas [20,21]. As diagnoses were based on index of clinical suspicion, some 
degree of misclassification between malaria and other SFIs might have occurred.
Second, we observed increases in the rate of all three morbidity outcomes after 6 months of 
life (pneumonia/SFI increased over 50%, the rate of diarrhea/growth faltering increased to 
more than four times, and the rate of malaria more than doubled). Although this might be 
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expected for malaria [20] and gastroenteritis [22,23], as the infant begins to crawl and get 
exposed to numerous environmental stimuli including new foods, increase in severe 
respiratory morbidity would not be expected at this stage in an HIV-uninfected population of 
infants [5]. The most likely explanation for this finding is weaning from breast milk at about 
6 months of age. As almost all infants in this cohort stopped breastfeeding at that time (by 
maternal report), we cannot directly evaluate what proportion of the increased morbidity was 
due to weaning. However, other studies from African settings [22–24] have concluded that 
weaning from breast milk is, at least partially, responsible for postweaning increases in the 
risk of gastroenteritis-related morbidity and of infant mortality.
Approximately, 50% increases in both serious gastrointestinal and respiratory morbidity 
were seen during the rainy season in our study, highlighting the complex relationships of the 
social and physical environment and infectious diseases. Method of infant feeding is an 
important factor in this interaction. During the rainy season, no breastfeeding was associated 
with a more pronounced weight for age Z-score decline than during the dry season in the 
Zambia Exclusive Breastfeeding Study (ZEBS) [25]. Others have also reported an 
association between rainy season and malnutrition in African and other resource-limited 
settings [26,27]. Rainy season and flooding have been associated with diarrheal outbreaks 
and increased infant mortality, particularly among nonbreastfed infants, even those HIV-
unexposed [28]. A study from Kenya showed a higher pneumonia-related mortality among 
children (age <5 years) residing in Nairobi’s slums in the rainy season [29], and a study 
from multiple African sites showed an all-cause mortality increase among children during 
the rainy season [8].
A surprising finding was the lack of correlation of rainy season with severe malaria 
morbidity. Other studies have also failed to confirm seasonal variation of deaths attributed to 
malaria [8].
Another unexpected, and, to our knowledge, not previously reported, finding was the 
association of low neutrophil counts at birth with infant morbidity and mortality beyond the 
immediate neonatal period. Although in a few (four of 19) cases, a low ANC at birth was 
due to a serious infection, most cases of low ANC counts at birth were seen in asymptomatic 
and seemingly healthy infants. This is attributed to ‘benign neutropenia’, which is prevalent 
among African populations [19]. Such neutropenia is largely believed to be without adverse 
health consequences [30]. However, the consistency of the observed association with all 
morbidity outcomes examined and with infant mortality strongly suggests that it is a marker 
of increased risk.
The introduction of cotrimoxazole prophylaxis midway through the trial provided a ‘natural 
experiment’ to evaluate its effects. Infant cotrimoxazole prophylaxis was significantly 
associated with lower frequency of severe respiratory/other infectious and gastrointestinal 
morbidity, and of severe malaria in uninfected infants in our study. This finding concurs 
with the findings of the Post-Exposure Prophylaxis in Infants (PEPI) Malawi study [24]. 
Reductions in hospitalizations, antibiotic prescriptions, and mortality among HIV-infected 
children have been reported from several African countries [31,32]. Not all studies have 
reported a benefit of cotrimoxazole for uninfected children, particularly with respect to 
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bacterial infections. In a small (N = 185) randomized study in rural Uganda, cotrimoxazole 
prophylaxis yielded a 39% reduction in malaria incidence, but no significant differences in 
the incidence of complicated malaria, diarrhea, pneumonia, hospitalizations, or deaths after 
the first 6 months of life [33]. In a nonrandomized study of 363 children in Durban, South 
Africa, where malaria is not endemic [34], cotrimoxazole prophylaxis was associated with a 
nonsignificant increase in diarrheal illness, and no significant difference in lower respiratory 
infections [34]. These findings indicate the need for further study of the role of 
cotrimoxazole in HIV-exposed uninfected children, particularly given the concerns of 
microbial resistance with widespread use [35,36]. However, the evidence provided herein by 
the large BAN cohort provides reassurance as to the benefits of cotrimoxazole prophylaxis 
for the health and survival of HIV-exposed infants.
There was no effect of maternal CD4+ T-cell count on infant morbidity and mortality. 
However, all mothers in the BAN study had CD4+ T-cell counts greater than 200 cells/μl. 
Maternal CD4 cell count less than 200 cells/μl has, in other studies, been associated with 
increased risk of all-cause infant sick clinic visits in the first year of life [5], possibly due to 
the mother’s poorer health and inability to care for the infant, or other factors such as greater 
opportunity for infant exposure to mother’s pathogens or immunologic abnormalities in the 
HIV-exposed infants [6].
The HIV-exposed uninfected mortality rate in the first 48 weeks of life in this study was 34 
per 1000 person-years (44.2 per 1000 person-years in the whole BAN cohort with inclusion 
of HIV-infected infants) [16]. The Malawi Demographic Health Survey estimated the infant 
mortality rate from 2005 to 2010 to be 66 per 1000 live births for the general infant 
population [37]; according to UNICEF 2009 data [38], the infant mortality rate in Malawi 
was 61 per 1000 person-years and according to the US Bureau of Census, 86 per 1000 
person-years [39]. The lower rate of mortality in our study is likely due to close follow-up 
associated with clinical trial implementation and potentially improved access to health 
facilities in the urban setting where BAN was implemented. Also, we are limited when 
making comparisons with 12-month mortality rates from other studies, as BAN infants were 
only followed to 48 weeks of life. Mortality among HIV-uninfected infants rose after 28 
weeks, the time of weaning for most infants in BAN. In the PEPI Malawi study, cumulative 
infant mortality for HIV-exposed uninfected infants at 12 months was 35 per 1000 among 
infants still breastfeeding, compared with 43 per 1000 for those previously weaned [24]. In 
the ZEBS study, a mortality rate of 94 per 1000 was observed among 749 HIV-uninfected 
infants by 12 months of age [40] and was substantially influenced by time of weaning.
Conclusion
In conclusion, this analysis of infant morbidity and mortality in the first 48 weeks of life 
from the large BAN study highlights the risks associated with stopping breastfeeding at 6 
months in a resource-poor setting, underscoring the value of continued breastfeeding beyond 
6 months of age (with appropriate antiretroviral prophylaxis), consistent with 2010 WHO 
guidelines [41]. It strengthens the evidence for a health and survival benefit of prophylactic 
cotrimoxazole in HIV-exposed uninfected infants in resource-poor settings. It also suggests 
that low WBC or ANC counts at birth may be a marker for higher infant morbidity and 
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mortality, and implies that ethnic neutropenia may not be as benign as previously thought. 
Furthermore, it indicates that birth weight between 2000 and 2499 g, associated with 12 
times the rate of neonatal mortality, may necessitate more frequent (such as weekly) follow-
up of such infants in the first month of life.
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Fig. 1. Cumulative rates of survival in HIV-uninfected infants from 0 to 48 weeks by infant white 
blood cell (WBC – in cells/μl) at delivery and *receipt of prophylactic infant cotrimoxazole 
started at 6 weeks of age
*Estimated using the extended Kaplan–Meier estimator.
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Table 1
Baseline characteristics for 2250 infants enrolled in the Breastfeeding, Antiretrovirals, and Nutrition study 
who were HIV-uninfected at 2 weeks of age.
N
Treatment arm
 Mother ARV 803 (35.7%)
 Infant ARV 815 (36.2%)
 No ARV 632 (28.1%)
Maternal nutritional supplement
 Yes 1133 (50.4%)
 No 1117 (49.6%)
Maternal marital status
 Married 2083 (92.6%)
 Other 167 (7.4%)
Maternal education
 ≤Primary 1457 (64.8%)
 >Primary 790 (35.2%)
Electricity in the homea
 Yes 197 (19.1%)
 No 836 (80.9%)
Mother started on cotrimoxazole
 Yes 956 (42.5%)
 No 1294 (57.5%)
Infant started on cotrimoxazole
 Yes 1519 (67.5%)
 No 731 (32.5%)
Birth weight
 2000–2499 g 174 (7.7%)
 ≥2500 g 2072 (92.3%)
Maternal CD4+ T-cell count during pregnancy
 200–350/μl 676 (30.0%)
 >350/μl 1574 (70.0%)
Maternal hemoglobin during pregnancy
 <10 g/dl 514 (22.9%)
 ≥10 g/dl 1732 (77.1%)
Infant WBC at delivery
 <9000 cells/μl 149 (6.8%)
 ≥9000 cells/μl 2043 (93.2%)
Infant neutrophil count at delivery
 ≤1500 cells/μl 19 (0.9%)
 >1500 cells/μl 2176 (99.1%)
Infant platelet count at delivery
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N
 <85 000/μl 38 (1.7%)
 ≥85 000/μl 2154 (98.3%)
ARV, antiretroviral; WBC, white blood cell.
a
Variable only collected on 46% of Breastfeeding, Antiretrovirals, and Nutrition (BAN) study participants.
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Table 4
Association of risk factors with neonatal and postneonatal mortality in HIV-uninfected infants.
Unadjusted Adjusteda
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Neonatal death (≤ 30 days; n = 10)
Treatment arm
 Mother ARV 0.79 (0.20–3.15) 0.54 0.76 (0.19–3.05) 0.56
 Infant ARV 0.38 (0.07–2.10) 0.39 (0.07–2.14)
 No ARV 1.0 1.0
Rainy seasonb
 Yes 3.60 (0.93–13.9) 0.06 –
 No 1.0
Maternal cotrimoxazoleb
 Yes 0.33 (0.07–1.54) 0.16 –
 No 1.0
Birth weight
 2000–2499 g 12.3 (3.56–42.5) < 0.001 12.3 (3.55–42.4) <0.001
 ≥ 2500 g 1.0 1.0
Maternal CD4+ T-cell count during pregnancy
 200–350/μl 1.57 (0.44–5.55) 0.49 –
 >350/μl 1.0
Maternal hemoglobin during pregnancy
 <10 g/dl 0.84 (0.18–3.96) 0.83 –
 ≥ 10 g/dl 1.0
Infant WBC at delivery
 <9000 cells/μl 1.51 (0.19–11.9) 0.70 –
 ≥ 9000 cells/μl 1.0
Infant neutrophil count at delivery
 ≤ 1500 cells/μl 13.2 (1.67–104) 0.02 –
 >1500 cells/μl 1.0
Infant platelet count at delivery
 <85 000/μl 6.3 (0.80–50.0) 0.08 –
 ≥ 85 000/μl 1.0
Postneonatal death (31 days to 48 weeks; n = 46)
Treatment arm
 Mother ARV 0.90 (0.43–1.86) 0.95 0.96 (0.46–2.00) 0.99
 Infant ARV 0.92 (0.45–1.89) 0.98 (0.48–2.02)
 No ARV 1.0 1.0
Rainy seasonb
 Yes 4.02 (2.08–7.76) < 0.001 4.24 (1.68–10.7) 0.002
 No 1.0 1.0
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Unadjusted Adjusteda
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Infant cotrimoxazoleb
 Yes 0.50 (0.26–0.96) 0.04 0.48 (0.25–0.93) 0.03
 No 1.0 1.0
Birth weight
 2000–2499 g 0.90 (0.28–2.91) 0.86 –
 ≥ 2500 g 1.0
Maternal CD4+ T-cell count during pregnancy
 200–350/μl 0.59 (0.29–1.23) 0.16 –
 >350/μl 1.0
Maternal hemoglobin during pregnancy
 <10 g/dl 1.15 (0.58–2.26) 0.69 –
 ≥ 10 g/dl 1.0
Infant WBC at delivery
 < 9000 cells/μl 2.58 (1.15–5.76) 0.02 2.53 (1.13–5.67) 0.02
 ≥ 9000 cells/μl 1.0 1.0
Infant neutrophil count at delivery
 ≤ 1500 cells/μl 3.34 (0.46–24.3) 0.23 –
 >1500 cells/μl 1.0
Infant platelet count at delivery
 <85 000/μl 2.83 (0.69–11.7) 0.15 –
 ≥ 85 000/μl 1.0
ARV, antiretroviral; CI, confidence interval; WBC, white blood cell.
a
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